The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Main Article Content

Melinda J. Gooderham
Leon H. Kircik
Matthew Zirwas
Mark Lee
Steven E. Kempers
Zoe D. Draelos
Laura Ferris
Terry M. Jones
Etienne Saint-Cyr Proulx
Robert Bissonnette
Neal Bhatia
Scott T. Guenthner
Robert A. Koppel
Howard Welgus
Charlotte Merritt
Meg Elias
Lynn Navale
Robert C. Higham
Michael Droege
David R. Berk

Keywords

Atopic Dermatitis, Phosphodiesterase Inhibitor, Topical, Proof of Concept

Abstract

Abstract not available.

References

1.Silverberg JI, et al. J Dermatolog Treat 2016;27:568-576.

2.BäumerW, et al. InflammAllergy Drug Targets2007;6:17-26.

3.Guttman-YasskyE, et al. Exp Dermatol2019;28:3-10.

4.Dong C, et al. J PharmacolExp Ther2016;358:413-422.

5.LebwohlMG, et al. N EnglJ Med 2020;383:229-239.